https://www.selleckchem.com/products/EX-527.html
Safety and dermal tolerability were evaluated. RESULTS After 12 weeks, facial acne was clear or almost clear in about 47 percent of patients. Inflammatory, noninflammatory, and total lesions decreased from baseline, with a greater reduction apparent in noninflammatory lesions. Systemic exposure to dapsone in PK patients was low. The overall rate of adverse events was low, and dermal tolerability scores indicated no or mild stinging/burning, dryness, scaling, and erythema. CONCLUSION Once-daily topical dapsone 7.5% gel used for 12 weeks w
Like
Comment
Share
